Virus-like particle (VLP) vaccines are an innovative class of vaccines that mimic the structure of viruses without containing any viral genetic material. These particles resemble the outer shell of a virus, allowing them to stimulate a strong immune response without the risk of causing disease. VLPs are created by expressing viral proteins in cells, which then assemble into non-infectious particles that resemble the virus. These vaccines are particularly useful for pathogens that are difficult to cultivate or study in traditional vaccine development methods. VLP vaccines have been successfully used in the development of vaccines for HPV (human papillomavirus) and hepatitis B. One of the advantages of VLP vaccines is their ability to generate both a humoral (antibody) and a cellular immune response, offering protection against future infections. This technology is a promising platform for developing vaccines for a wide range of diseases, including cancer and emerging viral infections.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States